http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2759332-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_536744f1fed8439775482b448beda1f3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6935 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-593 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6937 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 2010-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb8d4ec3860f291c6d9a6951ab3570f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e08ab0375305f23e71ad00c7e79dca2f |
| publicationDate | 2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2759332-A1 |
| titleOfInvention | Immunonanotherapeutics providing a th1-biased response |
| abstract | Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1 -biased immune response is desirable. In an aspect, the invention relates to a composition for treatment of a condition comprising: synthetic nanocarriers comprising (1) an immunofeature surface, an (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and a pharmaceutically acceptable excipient; wherein the immunofeature surface does not comprise antigen that is relevant to treatment of the condition in an amount sufficient to provoke an adaptive immune response to the antigen that is relevant to treatment of the condition. In another aspect, the invention relates to a method comprising: identifying a subject suffering from a condition; providing a composition that comprises synthetic nanocarriers that comprise (1) an APC targeting feature, and (2) a Th1 biasing immunostimulatory agent coupled to the synthetic nanocarriers; and a pharmaceutically acceptable excipient; and administering the composition to the subject; wherein the administration of the composition does not further comprise co-administration of an antigen that is relevant to treatment of the condition. In yet another aspect, the invention relates to a method comprising: providing a composition comprising synthetic nanocarriers that comprise a Th1 biasing immunostimulatory agent and an APC targeting feature; administering the composition to a subject; and administering an antigen to the subject to which a Th1 biased response is desired at a time different from administration of the composition to the subject; wherein administration of the antigen comprises passive administration or active administration. |
| priorityDate | 2009-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1149.